Page last updated: 2024-11-10

3,3',4-o-trimethylellagic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,7,8-tri-O-methylellagic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281860
CHEMBL ID451476
CHEBI ID1368
SCHEMBL ID941424
MeSH IDM0148811

Synonyms (33)

Synonym
nsc-333299
1617-49-8
nsc333299
ellagic acid,3',4-tri-o-methyl
3,4,3'-tri-o-methylellagic acid
C10836 ,
chebi:1368 ,
CHEMBL451476 ,
(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2-hydroxy-3,7,8-trimethoxy-
ellagic acid, 3,3',4-tri-o-methyl
3,7,8-tri-o-methylellagic acid
3,3',4-tri-o-methylellagic acid
3,3',4-o-trimethylellagic acid
nsc 333299
SCHEMBL941424
2,3,8-tri-o-methylellagic acid
surecn941424
DTXSID60167224
6-hydroxy-7,13,14-trimethoxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
AKOS032948448
6-hydroxy-7,13,14-trimethoxy-2,9-dioxatetracyclo[6.6.2.0^{4,16.0^{11,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
Q27105446
3,3',4-tri-o-methylellagic acid; 3,3',4'-trimethoxyellagic acid; 3,4,3'-tri-o-methylellagic acid; ellagic acid 3,3',4-trimethyl ether
bdbm50463328
methyl1-methyl-1h-indole-2-carboxylate
2-hydroxy-3,7,8-trimethoxy[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione
6-hydroxy-7,13,14-trimethoxy-2,9-dioxatetracyclo[6.6.2.0{4,16.0{11,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
D3NBF2EA6P
3,3',4'-trimethoxyellagic acid
ellagic acid 3,3',4-trimethyl ether
[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione, 2-hydroxy-3,7,8-trimethoxy-
diphenic acid, 4,6,6'-trihydroxy-4',5,5'-trimethoxy-, di-delta-lactone
FS-10445
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tanninAny of a group of astringent polyphenolic vegetable principles or compounds, chiefly complex glucosides of catechol and pyrogallol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription factor p65Homo sapiens (human)IC50 (µMol)1.60000.00011.89818.8000AID1398545
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID385094Inhibition of HIV1 reverse transcriptase at 200 ug/ml2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID385092Antiviral activity against deltaTat/Rev deffective HIV1 in 1A2 cells assessed as reduction of syncytium formation2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID384922Cytotoxicity against mouse P388 cells after 72 hrs by sulforhodamine B assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID384923Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID333823Antioxidant activity against lipid peroxidation in Wistar rat brain assessed as inhibition of malondialdehyde release at 25 ug/mL by thiobarbituric acid method relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID385091Antiviral activity against deltaTat/Rev deffective HIV1 in 1A2 cells assessed as inhibition of metabolic activity in uninfected cells2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID1398546Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID384925Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID333821Antioxidant activity against LDL-susceptible to oxidation in New Zealand White rabbit plasma assessed as increase in conjugated diene formation at 12.5 ug/mL after 30 mins2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID333820Antioxidant activity against LDL-susceptible to oxidation in New Zealand White rabbit plasma assessed as increase in conjugated diene formation at 25 ug/mL after 30 mins2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID338014Growth inhibition of mouse P388 cells
AID1398543Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID1398545Inhibition of biotinylated consensus sequence binding to NF-kB p65 in human HeLa nuclear extracts after 3 hrs by ELISA2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID333824Antioxidant activity against lipid peroxidation in Wistar rat brain assessed as inhibition of malondialdehyde release at 12.5 ug/mL by thiobarbituric acid method relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID385090Cytotoxicity against rat ASK cells after 72 hrs by sulforhodamine B assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID333822Antioxidant activity against lipid peroxidation in Wistar rat brain assessed as inhibition of malondialdehyde release at 50 ug/mL by thiobarbituric acid method relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID333819Antioxidant activity against LDL-susceptible to oxidation in New Zealand White rabbit plasma assessed as increase in conjugated diene formation at 50 ug/mL after 30 mins2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID384924Cytotoxicity against human Col2 cells after 72 hrs by sulforhodamine B assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
AID1398542Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID1398541Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID1398544Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID385089Cytotoxicity against human Lu1 cells after 72 hrs by sulforhodamine B assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's1 (10.00)18.2507
2000's4 (40.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]